PMAIP1抗体;PMAIP1 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using PMAIP1 mouse mAb (green) and negative control (red).    

  
  

The PMAIP1 (also known as Noxa) antibody is a key tool for studying the role of the PMAIP1 protein, a pro-apoptotic member of the Bcl-2 family. PMAIP1 is a BH3-only protein primarily involved in apoptosis regulation under cellular stress, such as DNA damage or oncogene activation. Its expression is tightly regulated by the tumor suppressor p53. though p53-independent pathways (e.g., HIF-1α, NF-κB) also contribute. PMAIP1 promotes apoptosis by binding and neutralizing anti-apoptotic Bcl-2 proteins (e.g., Mcl-1. A1), thereby activating Bax/Bak-dependent mitochondrial outer membrane permeabilization (MOMP) and caspase cascade initiation.

Antibodies targeting PMAIP1 are widely used in cancer research to investigate its role in tumor cell survival, chemoresistance, and response to therapies. They are employed in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein expression, localization, and interactions. Studies using PMAIP1 antibodies have revealed its dual role: while it induces apoptosis in some cancers, elevated PMAIP1 in others correlates with poor prognosis, suggesting context-dependent functions. Additionally, these antibodies aid in exploring PMAIP1's involvement in non-cancer pathologies, including neurodegenerative and autoimmune diseases.

Most commercial PMAIP1 antibodies are raised against human epitopes (e.g., aa 12-54) and show cross-reactivity with mouse and rat homologs. Validation includes knockout cell line controls to confirm specificity. Researchers must optimize protocols, as PMAIP1 has a short half-life and low basal expression, often requiring stress-inducing treatments (e.g., UV, etoposide) for detection.